doribax
Pharmaranks rates Doribax 3.6/5 for recall safety — an independent score from its FDA recall history and its manufacturer's record. Doribax (Doripenem) is a medication used to treat Urinary Tract Infections, Intraabdominal Infections.
Doripenem · by Shionogi
Based on 1 source · Recall-safety score from FDA recall history — this product's own recalls and its manufacturer's record. Not an efficacy or quality rating. methodology →
Key facts
- Active ingredient
- Doripenem
- Form
- Injectable
- Strength
- Doripenem 250MG/VIAL **Federal Register Determination That Product was not Discontinued or Withdrawn for Safety or Effectiveness reasons** · Doripenem 500MG/VIAL **Federal Register Determination That Product was not Discontinued or Withdrawn for Safety or Effectiveness reasons**
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- Manufacturer
- Shionogi
- FDA application
- NDA022106
- Availability
- Discontinued (per FDA)
May treat (source: NIH RxClass)
Dosage forms
Injectable
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Doribax treat?
- Doribax (Doripenem) may be used to treat urinary tract infections, intraabdominal infections, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How is Doribax rated?
- pharmaranks gives Doribax a composite score of 3.6 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.
- Is there a coupon or discount for Doribax?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Doribax. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Doribax?
- Doribax is marketed by Shionogi. You can see Shionogi's full profile, rating, and other products on pharmaranks.
- Is Doribax a brand-name or generic drug?
- Doribax is a brand-name product with the active ingredient Doripenem.
- Is Doribax available over the counter?
- No. Doribax is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Doribax come in?
- Doribax is currently marketed as injectable, per the FDA's National Drug Code Directory.
- Is Doribax FDA-registered?
- Doribax is on record with the U.S. FDA under application number NDA022106. You can verify this on its official FDA label.
- Has Doribax been recalled by the FDA?
- Doribax has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.
- Is Doribax safe?
- There's no single safe-or-not verdict. pharmaranks gives Doribax a recall-safety score of 72/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about DORIPENEM
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 647 reports naming DORIPENEM — the active ingredient in Doribax, and the FDA flagged 96% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- pneumonia76 reports
- pyrexia62 reports
- sepsis62 reports
- febrile neutropenia38 reports
- diarrhoea31 reports
- platelet count decreased31 reports
- respiratory failure28 reports
- renal failure27 reports
Read these as a signal, not a rate. A report does not mean DORIPENEM caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 25, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
blujepa
Gepotidacin Mesylate
cayston
Aztreonam
fetroja
Cefiderocol Sulfate Tosylate
azactam
Aztreonam
cranberry
Cranberry Extract
d-mannose
D-Mannose
Compare Doribax head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
doribax
72/100